The study combines transcriptomic and genomic data from ESCC patients to identify immune biomarkers. Credit: PeopleImages/Shutterstock.com.
BostonGene and Kyoto University have collaborated to advance precision drug development for oesophageal squamous cell carcinoma.
This collaboration is intended for the development of advanced biological signatures to improve targeted treatment strategies.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
It centres on leveraging BostonGene’s AI-powered omnimodal platform to analyse tumour molecular profiles and evaluate their response to a new combination of chemoradiotherapy (CRT) and immune checkpoint inhibitors (ICI).
The research expands upon the investigator-initiated Phase II Nobel clinical study led by Dr Manabu Muto of Kyoto University.
By combining transcriptomic and genomic data from the patients, the study aims to identify immune-related biomarkers that improve trial design, facilitate accurate stratification of patients and advance drug development.
Kyoto University will provide patient data and clinical samples, while BostonGene utilises its AI-driven molecular analytics to identify biological pathways and biomarkers associated with treatment outcomes.
BostonGene Japan president Yukimasa Shiotsu stated: “This collaboration will generate actionable insights into the tumour microenvironment and immune landscape of oesophageal cancer.”
Dr Muto stated: “Understanding the molecular and immune characteristics of oesophageal squamous cell carcinoma is essential for developing more effective treatment strategies.
“Through this collaboration, we will apply cutting-edge AI-powered analytics to clinical data, enabling us to identify biomarkers that can directly inform treatment decisions and improve patient outcomes.”
The Nobel trial assesses the safety and efficacy of the combined CRT and ICI regimen in advanced oesophageal cancer. This investigator-initiated study is financially supported by Ono Pharmaceutical.
BostonGene Japan is a joint venture formed by BostonGene, Japan Industrial Partners and the NEC Corporation.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Pharmaceutical Technology Excellence Awards – The Benefits of Entering
Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!
Nominate Now
AloJapan.com